Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 18/20 | 0.56 |
| ▸ | NPY1R | P25929 | 11/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.56 |
| ▸ | NPY2R | P49146 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666886 | 0.96 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29666900 | 0.96 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30531629 | 0.95 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29531807 | 0.95 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30490413 | 0.94 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30355277 | 0.94 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29385243 | 0.94 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30272464 | 0.93 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29872588 | 0.92 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29666908 | 0.92 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11628202-B2 | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia | NYMOX CORPORATION (CA) | 2023-04-18 | — | — | US | claimed |
| US-12090191-B2 | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS | NYMOX CORPORATION (BS) | 2024-09-17 | — | — | US | disclosed |
| US-20240252516-A1 | COMBINATION BPH THERAPY WITH FEXAPOTIDE TRIFLUTATE, A 5-ARI, AND AN ALPHA BLOCKER | NYMOX CORPORATION | 2024-08-01 | — | — | US | disclosed |
| CN-110381984-B | Compositions and methods for improving sexual function | 尼莫克斯股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20220226424-A1 | METHOD OF ENHANCING THE THERAPEUTIC EFFICACY OF FEXAPOTIDE TRIFLUTATE IN TREATING LUTS | NYMOX CORPORATION | 2022-07-21 | — | — | US | disclosed |
| EP-4003387-A1 | FOCAL TREATMENT OF PROSTATE CANCER | Nymox Corporation (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4003533-A1 | METHODS OF TREATING MULTIFOCAL CANCER | Nymox Corporation (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11298400-B2 | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS | NYMOX CORPORATION (BS) | 2022-04-12 | — | — | US | disclosed |
| EP-3969112-A1 | METHOD OF TREATING LOWER URINARY TRACT SYMPTOMS WITH FEXAPOTIDE TRIFLUTATE | Nymox Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3969030-A1 | METHOD OF ENHANCING THE THERAPEUTIC EFFICACY OF FEXAPOTIDE TRIFLUTATE IN TREATING LUTS | Nymox Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11278588-B2 | Method of treating lower urinary tract symptoms with fexapotide triflutate | NYMOX CORPORATION (BS) | 2022-03-22 | — | — | US | disclosed |